Center for Advanced Multi-Omic Characterization of Cancer

癌症高级多组学表征中心

• 批准号: 10755578
• 负责人: Tao Liu
• 金额: $ 51.68万
• 依托单位: BATTELLE PACIFIC NORTHWEST LABORATORIES
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-06-01 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10755578
• 关键词: Acceleration; Acute Myelocytic Leukemia; Acute T Cell Leukemia; Cells; Center for Translational Science Activities; Child; Childhood; Childhood Leukemia; Clinical; Clinical Trials; Collaborations; Colorectal Cancer; Communities; Country; Data; Data Analyses; Defect; Disease; Funding; Future; Genome; Genomics; Immunotherapy; Investments; Label; Laboratories; Liquid Chromatography; Malignant Childhood Neoplasm; Malignant Neoplasms; Malignant neoplasm of ovary; Mass Spectrum Analysis; Molecular; National Cancer Institute; Pacific Northwest; Pathway interactions; Pediatric Research; Phenotype; Phosphorylation; Post-Translational Protein Processing; Proteins; Proteome; Proteomics; Relapse; Resistance; Resources; Sampling; Signal Pathway; Standardization; Toxic effect; United States National Institutes of Health; anticancer research; cancer type; driver mutation; genome analysis; high risk; insight; instrumentation; leukemia; malignant breast neoplasm; multiple omics; novel; novel therapeutics; open source; precision oncology; programs; proteogenomics; tandem mass spectrometry; targeted treatment; tumor

PROJECT SUMMARY The National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. Launched in 2011, CPTAC pioneered the integrated proteogenomic analysis of colorectal, breast and ovarian cancer to reveal new insights into these cancer types, such as identification of proteomic-centric subtypes, prioritization of driver mutations by correlative analysis of copy number alterations and protein abundance, and understanding cancer-relevant pathways through post- translational modifications. In this project, CPTAC will collaborate with the NIH Common Fund Gabriella Miller Kids First Pediatric Research Program (Kids First) to comprehensively characterize pediatric leukemia samples (such as T-cell acute lymphoblastic leukemia, T-ALL, and acute myeloid leukemia, AML) using mass spectrometry-based proteomics. This project will fully integrate proteogenomic information of such leukemia samples to capture and replicate specific cancer phenotype, better understand the interconnection of cancer pathways, identify novel protein targets for targeted therapies and immunotherapies, and to stimulate future pediatric cancer research and precision oncology. The PNNL PCC will perform comprehensive, integrated global proteome and phosphoproteome analyses of a total of 272 pediatric leukemia samples provided by the Kids First collaborators in various forms (such as cell pellets and surfaceome samples), using state-of-the-art liquid chromatography-tandem mass spectrometry instrumentation, highly multiplexed isobaric mass-tag labeling (TMT 18-plex), and integrated sample workflows. The resulting molecular data will become a community resource available at CAVATICA.

项目摘要 国家癌症研究所的临床蛋白质组学肿瘤分析财团（CPTAC）是一项全国性的努力 通过应用大规模蛋白质组来加速对癌症分子基础的理解 和基因组分析或蛋白质组学。 CPTAC于2011年推出，开创了整合的蛋白质组学 分析结直肠癌，乳腺癌和卵巢癌，以揭示对这些癌症类型的新见解，例如 以蛋白质组学为中心的亚型鉴定，通过副本的相关分析来优先考虑驱动器突变 数量改变和蛋白质抽象，并通过后了解与癌症相关的途径 翻译修改。 在这个项目中，CPTAC将与NIH普通基金Gabriella Miller儿童合作 研究计划（儿童首先），以全面描述小儿白血病样品（例如T细胞 使用基于质谱的急性淋巴细胞白血病，T-ALL和急性髓样白血病，AML） 蛋白质组学。该项目将充分整合此类白血病样本的蛋白质组信息以捕获和 复制特定的癌症表型，更好地了解癌症途径的互连，识别新型 靶向疗法和免疫疗法的蛋白质靶标，并刺激未来的小儿癌研究 和精度肿瘤学。 PNNL PCC将对A进行全面的，整合的全球蛋白质组和磷蛋白质组分析 孩子们共同提供了272个小儿白血病样本，由孩子们以各种形式提供的第一合作者（例如细胞） 颗粒和表面样品），使用最先进的液相色谱量质谱法 仪器，高度多路复用的同质质量标签标签（TMT 18-plex）和集成样品 工作流程。由此产生的分子数据将成为Cavatica可用的社区资源。